STOCK TITAN

Co-Diagnostics Inc - CODX STOCK NEWS

Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.

Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics innovator developing PCR-based testing solutions through its patented Co-Primers™ technology. This page serves as the definitive source for verified company news and announcements, providing stakeholders with timely updates on developments impacting global healthcare diagnostics.

Investors and industry professionals will find curated press releases covering financial results, regulatory milestones, product launches, and strategic partnerships. Our aggregation includes updates on CODX's expanding test menu (including tuberculosis and respiratory disease diagnostics), manufacturing expansions, and progress toward decentralized testing solutions through the Co-Dx™ platform.

Key resources include earnings call transcripts, FDA clearance announcements, and analysis of emerging market initiatives like the CoSara Diagnostics joint venture in India. All content is organized chronologically demonstrate the company's trajectory while maintaining compliance with financial disclosure standards.

Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis. Check regularly for updates on CODX's contributions to accessible, high-accuracy diagnostic testing worldwide.

Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in the Yale School of Public Health SalivaDirect™ Conference on July 28-29 in Chicago. The conference focuses on promoting saliva-based testing for infectious diseases. CEO Dwight Egan and Chairman of the Scientific Advisory Board Dr. Carl Wittwer will present on the topic "The Opportunity for A New Global Response To Infectious Disease" on July 29th at 3:00 PM CT. Co-Diagnostics specializes in molecular diagnostics, developing advanced technologies for testing infectious diseases and genetic markers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced a global expansion of its OEM agreement with Bio Molecular Systems (BMS) during its update at AACC. This expanded agreement increases Co-Dx's approved sales territories to 193 countries, building on existing sales in over 50 countries. BMS, known for its expertise in PCR technology, manufactures the Co-Dx Box™, enhancing the user experience of Co-Diagnostics' molecular assays. CEO Dwight Egan expressed optimism about the growth opportunities this collaboration presents for expanding the reach of their affordable and high-quality molecular testing tools.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) will showcase its diagnostics products at the AACC Annual Scientific Meeting & Clinical Lab Expo from July 24-28 in Chicago, IL. The Company invites distributors and customers for a global update on July 26 at 11 am CT in room S103A. CEO Dwight Egan will present on the Co-Dx PCR Home testing platform at 2 pm CT on July 26. Co-Dx has sold over 34 million PCR tests across more than 50 countries. The Co-Dx PCR Home testing platform is under FDA review and not yet available for sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
conferences
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced the shipment of testing reagents for monkeypox virus to an international distributor amidst a global outbreak. As of July 7, 2022, over 6,000 monkeypox cases have been reported across 59 countries, according to the World Health Organization. The reagents were developed quickly to meet urgent regional demands. CEO Dwight Egan emphasized the importance of their PCR-based testing products for effective disease detection, underscoring the company's commitment to high-quality, affordable diagnostics worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced its presentation at the 29th International Biodetection Technologies Conference, held virtually on June 28-29, 2022. CEO Dwight Egan will discuss the upcoming PCR Home testing platform during the Point-of-Care Diagnostics agenda on June 29 at 12:30 pm ET. This conference focuses on the latest innovations in the detection and identification of biological threats. An archived version of the presentation will be available on the company's website post-conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
conferences
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced that key executives will participate in the Sidoti Summer Small Cap Virtual Investor Conference on June 15-16, 2022. CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson will present and hold one-on-one meetings with investors. The presentation starts at 3:15 p.m. EDT on June 15 and can be accessed via the company's website. Co-Diagnostics specializes in molecular diagnostics, focusing on developing tests that analyze nucleic acid molecules for various applications, including infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
conferences
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) is participating in the 22nd MEDEXPO Africa 2022 in Nairobi, Kenya from June 9-11. This significant event showcases over 30 countries' medical technology solutions, aiming at buyers seeking innovative products and services. This marks Co-Dx's first trade show in Africa, enhancing its initiative to promote COVID-19 and other infectious disease tests across the continent. Notably, the company has completed the design of a PCR test for monkeypox. Interested attendees can find Co-Dx at Booth #124.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
conferences
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) has completed the principal design of a PCR test for the monkeypox virus, amid a multi-country outbreak. The test will leverage the Company's patented CoPrimer™ technology and proprietary software system. CEO Dwight Egan emphasized the need for prompt action against potential outbreaks, highlighting Co-Dx's mission to enhance access to affordable, high-quality molecular testing globally. The World Health Organization reported monkeypox cases in 18 non-endemic countries since May 13, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation at the H.C. Wainwright & Co. 2022 Global Investment Conference, scheduled for May 23-26 in Miami, Florida. CEO Dwight Egan will present on May 25 at 1:30 PM ET, discussing the company's recent performance and its new Co-Dx PCR Home Diagnostic Platform. Egan highlighted Florida's significance as a market, contributing over $28 million in revenue since the pandemic began. The conference aims to engage institutional investors and industry professionals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences
Rhea-AI Summary

Co-Diagnostics, Inc. (NASDAQ: CODX) reported record first-quarter revenue of $22.7 million and a diluted EPS of $0.34 for the period ending March 31, 2022. Revenue growth was driven mainly by sales of the Logix Smart™ COVID-19 Test. Gross profit rose to $19.4 million, reflecting an 85.5% gross margin. However, operating income slightly decreased to $9.8 million due to increased R&D expenses. Cash reserves increased to $97.4 million, providing a strong foundation for future growth. Despite positive results, management highlighted challenges in forecasting future COVID-19 test sales due to changing market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.9%
Tags
Co-Diagnostics Inc

Nasdaq:CODX

CODX Rankings

CODX Stock Data

11.66M
31.36M
6.7%
18.02%
0.61%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SALT LAKE CITY